Bristol Myers Squibb’s Zola-Cel Shows Early Efficacy in Phase 1 Multiple Sclerosis Trial

Bitget2026/10/23 14:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bristol Myers Squibb is presenting interim Phase 1 Breakfree-2 results for investigational multiple sclerosis therapy zola-cel today at MSToronto 2026.
Early findings showed potential to control relapses and stabilize disability in patients with highly active relapsing or progressive disease.
All patients receiving the higher dose remained off disease-modifying therapies at last follow-up, including some followed for more than a year.
Most adverse events were brief and reversible; one severe neurological event resolved with treatment.
Following the data cutoff, one patient died from septic pneumonia following high-dose cyclophosphamide treatment for unresolved motor symptoms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202610231030BIZWIRE_USPR_____20261022_BW949204) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bristol Myers Squibb’s Zola-Cel Shows Early Efficacy in Phase 1 Multiple Sclerosis Trial

You may also like

Crypto prices